Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02206204 · ClinicalTrials.gov registry record · Phase 1
Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
A Phase 1 study of Pharmacokinetics and Safety, sponsored by Actelion.
- Completed
- Registry status
- Phase 1
- Development phase
- 159
- Enrollment target
- 1
- Study location
NCT02206204 is a Phase 1 study of Pharmacokinetics and Safety that has completed, run by Actelion. The registered enrollment target is 159 participants, above the 58-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (174% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02206204, a Phase 1 study of Pharmacokinetics and Safety, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 159 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, double-blind, randomized, placebo- and positive-controlled, double-dummy, parallel-group, multiple-dose, up-titration study with a nested cross-over comparison between moxifloxacin and placebo in healthy male and female subjects. The primary objective is to demonstrate that selexipag and its metabolite ACT-333679 do not have an effect on cardiac repolarization exceeding the threshold of regulatory concern, at two orally administered dose levels (800 and 1600 μg twice daily) in healthy male and female subjects. Moxifloxacin is included as a positive control.
Conditions Studied
Interventions
- DRUG moxifloxacin
- DRUG selexipag
- DRUG placebo for selexipag
- DRUG moxifloxacin-matching placebo
Study Locations (1)
Indiana
- Covance Clinical Research Unit - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02206204
The ClinicalTrials.gov registry entry for NCT02206204 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 58-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (174% higher). The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pharmacokinetics appearing as the primary indexed condition, and to 4 interventions - of which moxifloxacin is the first listed.
NCT02206204 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT02206204 about?
NCT02206204 is a clinical study titled "Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects". This is a single-center, double-blind, randomized, placebo- and positive-controlled, double-dummy, parallel-group, multiple-dose, up-titration study with a nested cross-over comparison between moxifloxacin and placebo in healthy male and female subjects. The primary objective is to demonstrate that ...
What is the current status of trial NCT02206204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 159 participants. The study started on 2012-06. Estimated completion is 2012-11.
What conditions does trial NCT02206204 study?
This clinical trial studies the following conditions: Pharmacokinetics, Safety, Tolerability, Cardiodynamics.
What interventions are being tested in trial NCT02206204?
The interventions under investigation include: moxifloxacin (DRUG), selexipag (DRUG), placebo for selexipag (DRUG), moxifloxacin-matching placebo (DRUG).
Who is sponsoring clinical trial NCT02206204?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02206204 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.